It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We assessed the prognostic value of five complex inflammatory and nutritional parameters, namely neutrophil-to-lymphocyte ratio (NLR), prognostic nutritional index (PNI), C-reactive protein-to-NLR ratio (C/NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) using data from patients with malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy (EPP). Moreover, the correlation between these five parameters and programmed cell death protein 1 ligand-1 (PD-L1) expression in the tumor microenvironment was evaluated. This study included consecutive MPM patients who underwent EPP. The histological subtype of the eligible patients (n = 61) correlated with all five parameters. Moreover, the PD-L1 expression scores for immune cells correlated with NLR and PLR, and the PD-L1 expression scores for both tumor cells and immune cells were inversely correlated with both PNI and LMR. Univariate analysis elucidated that NLR, PNI, and C/NLR were predictors of 5-year overall survival (OS), and multivariate analysis revealed that NLR was an independent predictor of 5-year OS, suggesting that NLR is a preoperative, prognostic factor for patients with MPM who are scheduled for EPP. To the best of our knowledge, this is the first study to evaluate the prognostic potentials of NLR, PNI, C/NLR, PLR, and LMR simultaneously in patients with MPM who underwent EPP.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 National Hospital Organization Yamaguchi Ube Medical Center, Department of Thoracic Surgery, Ube Yamaguchi, Japan (GRID:grid.415694.b) (ISNI:0000 0004 0596 3519)
2 Yamaguchi University Graduate School of Medicine, Health Administration Center, Ube, Yamaguchi, Japan (GRID:grid.268397.1) (ISNI:0000 0001 0660 7960)
3 National Hospital Organization Yamaguchi Ube Medical Center, Department Clinical Research, Ube Yamaguchi, Japan (GRID:grid.415694.b) (ISNI:0000 0004 0596 3519); KYURIN/ KYURIN PACELL Corporation, Department of Pathology, Kitakyushu, Japan (GRID:grid.415694.b)
4 National Hospital Organization Yamaguchi Ube Medical Center, Department Clinical Research, Ube Yamaguchi, Japan (GRID:grid.415694.b) (ISNI:0000 0004 0596 3519); Yamaguchi University Graduate School of Medicine, Department of Pathology, Ube, Yamaguchi, Japan (GRID:grid.268397.1) (ISNI:0000 0001 0660 7960)